抗菌浸渍中心静脉导管预防新生儿血流感染(PREVAIL):一项开放标签、平行组、实用性、随机对照试验
该试验在英格兰18个新生儿重症监护病房纳入需经外周置入中心静脉导管(PICC)的新生儿861例,随机接受米康唑和利福平浸渍PICC或标准PICC。
要点
- 米康唑和利福平浸渍PICC未降低新生儿血行或脑脊液感染风险。
- 抗菌浸渍PICC组导管尖端阳性培养利福平耐药率显著升高。
- 两组导管留置时间、死亡及出院时临床结局无显著差异。
核心结论
- 与标准PICC相比,米康唑和利福平浸渍PICC对新生儿无获益或伤害证据。
研究设计与样本
- 开放标签、平行组、实用性、随机对照试验,在英格兰18个新生儿重症监护病房进行。
- 纳入需PICC的新生儿861例,1:1随机分配至抗菌浸渍PICC组(430例)或标准PICC组(431例)。
- 主要结局为随机分配后24小时至PICC拔除或死亡后48小时内首次微生物学确认的血行或脑脊液感染时间。
主要发现
- 抗菌浸渍PICC组46/430例(11%)与标准PICC组44/431例(10%)发生微生物学确认的血行或脑脊液感染。
- 抗菌浸渍PICC组49/430例(13%)报告60次不良事件,标准PICC组45/431例(10%)报告50次不良事件。
关键数值与推荐
- 主要结局采用意向性分析,安全性分析排除未置入PICC的婴儿。
- 随机分配通过中央控制的网络程序进行,采用随机区组(2和4)并按中心分层。
临床怎么用
- 不推荐为预防新生儿血流感染常规使用米康唑和利福平浸渍PICC。
- 需关注抗菌浸渍PICC可能诱导利福平耐药。
局限性
- 开放标签设计,因利福平导致PICC棕色染色无法对临床医生设盲。
- 研究仅评估米康唑和利福平浸渍PICC,结果不能推广至其他抗菌浸渍类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bloodstream infection is associated with high mortality and serious morbidity in preterm babies. Evidence from clinical trials shows that antimicrobial-impregnated central venous catheters (CVCs) reduce catheter-related bloodstream infection in adults and children receiving intensive care, but there is a paucity of similar evidence for babies receiving neonatal intensive care. METHODS: This open-label, parallel-group, pragmatic, randomised controlled trial was done in 18 neonatal intensive care units in England. Newborn babies who needed a peripherally inserted CVC (PICC) were allocated randomly (1:1) to receive either a PICC impregnated with miconazole and rifampicin or a standard (non-antimicrobial-impregnated) PICC. Random allocation was done with a web-based program, which was centrally controlled to ensure allocation concealment. Randomisation sequences were computer-generated in random blocks of two and four, and stratified by site. Masking of clinicians to PICC allocation was impractical because rifampicin caused brown staining of the antimicrobial-impregnated PICC. However, participant inclusion in analyses and occurrence of outcome events were determined following an analysis plan that was specified before individuals saw the unblinded data. The primary outcome was the time from random allocation to first microbiologically confirmed bloodstream or cerebrospinal fluid (CSF) infection between 24 h after randomisation and 48 h after PICC removal or death. We analysed outcome data according to the intention-to-treat principle. We excluded babies for whom a PICC was not inserted from safety analyses, as these analyses were done with groups defined by the PICC used. This trial is registered with ISRCTN, number 81931394. FINDINGS: Between Aug 12, 2015, and Jan 11, 2017, we randomly assigned 861 babies (754 [88%] born before 32 weeks of gestation) to receive an antimicrobial-impregnated PICC (430 babies) or standard PICC (431 babies). The median time to PICC removal was 8·20 days (IQR 4·77-12·13) in the antimicrobial-impregnated PICC group versus 7·86 days (5·00-12·53) days in the standard PICC group (hazard ratio [HR] 1·03, 95% CI 0·89-1·18, p=0·73), with 46 (11%) of 430 babies versus 44 (10%) of 431 babies having a microbiologically confirmed bloodstream or CSF infection. The time from random allocation to first bloodstream or CSF infection was similar between the two groups (HR 1·11, 95% CI 0·73-1·67, p=0·63). Secondary outcomes relating to infection, rifampicin resistance in positive blood or CSF cultures, mortality, clinical outcomes at neonatal unit discharge, and time to PICC removal were similar between the two groups, although rifampicin resistance in positive cultures of PICC tips was higher in the antimicrobial-impregnated PICC group (relative risk 3·51, 95% CI 1·16-10·57, p=0·018). 60 adverse events were reported from 49 (13%) patients in the antimicrobial-impregnated PICC group and 50 events from 45 (10%) babies in the standard PICC group. INTERPRETATION: We found no evidence of benefit or harm associated with miconazole and rifampicin-impregnated PICCs compared with standard PICCs for newborn babies. Future research should focus on other types of antimicrobial impregnation of PICCs and alternative approaches for preventing infection. FUNDING: UK National Institute for Health Research Health Technology Assessment programme.
引用
- Gilbert R, Brown M, Rainford N, et al. Antimicrobial-impregnated central venous catheters for prevention of neonatal bloodstream infection (PREVAIL): an open-label, parallel-group, pragmatic, randomised controlled trial. Lancet Child Adolesc Health. 2019. PMID: 31040096. doi:10.1016/S2352-4642(19)30114-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。